WHO ICTRP trial
?Efficacy and Safety of Iparomlimab/Tuvorlimab (QL1706) in Treating Intermediate…
ChiCTR2500101129 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500101129 |
|---|---|
| Public title | ?Efficacy and Safety of Iparomlimab/Tuvorlimab (QL1706) in Treating Intermediate Trophoblastic Tumors: A Prospective, Multicenter, Single-Arm Clinical Trial?? |
| Scientific title | ?Efficacy and Safety of Iparomlimab/Tuvorlimab (QL1706) in Treating Intermediate Trophoblastic Tumors: A Prospective, Multicenter, Single-Arm Clinical Trial?? |
| Primary sponsor | Peking Union Medical College Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Intermediate trophoblastic tumors |
| Interventions | QL1706 treatment group:QL1706;QL1706 and chemotherapy group:QL1706 plus chemotherapy |
| Registration date | Apr 21, 2025 |
| Target size | QL1706 treatment group:10;QL1706 and chemotherapy group:10 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: